John Frater University of Oxford

Slides:



Advertisements
Similar presentations
P OINT OF CARE TESTING Lecture 6. D EFINITION Medical testing at or near the site of patient care. It is a mode of analysis which is performed at the.
Advertisements

Informed Consent and Patient Involvement in Trials Norbert Tamm Research Charge Nurse Imperial College & St. Mary’s Hospital London.
Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics.
The Current Pipeline for Point-of-Care Virologic Testing for HIV/AIDS Scaling up Virologic Diagnostic HIV Testing in Infants and Rationalizing Decentralization.
Use of Dried Blood Spots (DBS) Specimens for Measuring HIV-1 Viral Load in Argentina M. Lorena Vázquez Inés Zapiola Ana Gun Silvia Gómez Alejandro Krolewiecki.
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
HCV Diagnostics Technology Landscape AIDS 2014, 10 th International AIDS Conference 21 July 2014 Maurine M. Murtagh UNITAID Consultant.
Challenges in Scaling Up VL in Resource Limited Settings Collins Otieno Odhiambo KEMRI/CDC.
HIV Testing CDC power point edited by M. Myers
Laboratory Investigation
 The HIV virus can mutate in HIV positive patients taking Anti-Retroviral Therapy (ART)  Their HIV strain has now become drug resistant (DR), and their.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,
Poor Reproducibility of HIV­1 Low-level Viraemia Results with 3 Commercial Real-time PCR Assays Jean Ruelle 1, Laurent Debaisieux 2, Ellen Vancutsem 3,
Management of the Newly Diagnosed Patient. Jane Bruton Clinical Research Nurse Imperial College.
Early Infant Diagnosis: Current Tools and Prospects of Point of Care Technology Susan A. Fiscus, Ph.D. University of North Carolina at Chapel Hill.
Charlie Masiku Deputy Medical Coordinator MSF HIV Project, Chiradzulu, Malawi Capetown 22nd September 2014 Early experience with implementation of SAMBA.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
UNITED STATES CONFERENCE ON AIDS MONDAY, SEPTEMBER 9, 2013 NEW ORLEANS, LA Will Community Involvement in Test Link to Care, Plus Treat Research (HPTN 065)
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
Background Appropriate time to start HAART is still debatable 1995: “Time to hit HIV, early and hard” Eradication thought to be possible Early regimens.
Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,
A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland S O’Connell 1, D Lillis.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Evaluation of two techniques for viral load monitoring on DBS ANRS project Phase I - Laboratory.
Phar. Nhat Mang/ Roche Vietnam
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
Evaluating a novel semi-quantitative viral load test in the field: field trial for patient monitoring in Malawi and Uganda Dr. Suna Balkan MSF.
1 © Cepheid Early Infant Diagnosis (EID): Strategies and Options © Cepheid Philippe JaconPhilippe Jacon President, Emerging MarketsPresident, Emerging.
HIV Point of Care tests in Babies Study (BABY) Operational evaluation of HIV Point of Care tests for very early infant HIV diagnostics in infants born.
G. E. Martin. , N. Pantazis. , M. Hoffmann. , S. Hickling, J. Hurst, J
Xpert HIV-1 Viral Load: Beyond Plasma
Post natal integrated clubs as a way to improve retention in care of mother infant pairs in a primary care setting, Khayelitsha, South Africa. Aurélie.
Switch to PI/r monotherapy
Cepheid Symposium IAS 2017 Gwynn Stevens, PhD Director of Virology
RALTEGRAVIR vs LPV/R FOR LATE-PRESENTERS PREGNANT WOMEN.
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
Comparing Conventional to Point-of-Care (POC) Early Infant Diagnosis (EID): Pre and post intervention data from a multi-country evaluation. Flavia Bianchi,
Emory University School of Medicine Department of Medicine
A new era in home-based Screening and Monitoring
Absorbance: Enzyme Linked Immunosorbent Assays (ELISA)
Gaps in the cascade of care in two high prevalence settings in Zimbabwe and Malawi Nolwenn Conan1, Cyrus Paye2, Erica Simons2, Abraham Mapfumo3, Tsitsi.
20l of whole blood + 80 l of water +80 l of 0.1M ZnSO4
Point-of-Care EID and VL Products: What’s in the Pipeline?
Jessica Haberer, MD, MS July 24, 2017
Evaluation of Alere q HIV-1/2 VL Plasma
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Dr Lindi Coetzee Ms Keshendree Moodley Prof D.K. Glencross
HIV-1 PLASMA VIRAL LOAD IN TREATMENT NAÏVE HIV-1 PATIENTS
Diagnosis and Point of Care Testing of Hepatitis C
VL patient support: General education at different levels
Update on CBER HIV-1 Subtype panel
Follicular CD8+ T-cells (fCD8) in GALT are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during PHI John Thornhill Imperial.
ELISA Immuno ExlorerTM HIV/AIDS Diagnostic Tool
بسم الله الرحمن الرحیم.
Volume 5, Issue 6, Pages (June 2002)
Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots Beth Catlett In this study we evaluated.
From trials to programmes: Lessons learned from four trials of Universal Testing and Treatment (UTT) in Sub-Saharan Africa 24th July 2018 Estimates of.
Self Management of Diabetes for Persons with HIV
Hellen Mahiga, Study Clinician
Performing Sedia Asante: Testing algorithm
Performing Maxim Swift RIA: Testing algorithm
ANALYSIS OF vocS IN POC HEALTH SCREENING BREATHSPEC SANti dominguez CEO May 31st 2019.
Performance of mPima for quantification of HIV Viral load for pregnant and post-partum woman in primary health care clinics in Mozambique Team: B. Meggi.
Keep control: Elite and post-treatment controllers
PathTracker Smartphone System for Detecting Bacteria and Viruses
Introduction and current status of viral load access
Presentation transcript:

John Frater University of Oxford The UNICORN study - Whole blood finger-prick sampling for rapid and convenient PoC HIV viral load measurement Poster MOPEB0264
 Monday, 24 July 2017, 12:30 – 14:30 John Frater University of Oxford

Background PoC HIV diagnostics is widely available PoC HIV plasma viral load (pVL) is not PoC pVL testing would revolutionise the way we manage HIV: In high burden settings In low resource, low infrastructure settings For clinical trials requiring rapid and regular monitoring Eg Treatment Interruption studies for cure interventions

Rationale: the PITCH study Prospective Interruption of Therapy Towards a Cure for HIV (PITCH) Aim: To prospectively study mechanisms of post-treatment control after ART in Primary HIV Infection N=20; Pilot study Intensively Monitored Treatment Interruption (IMTI) IMTI Protocol involves pVL testing up to 3 times per week HOW BEST TO DO THIS?

Protocol dilemma: Quantitative or Qualitative monitoring?? More data ?too much data Only available from plasma Needs central lab 1ml plasma Qualitative Simple read-out Detectable:Yes/No Need to define cut-off Might be able to run from whole blood ? Could be done from a fingerprick

UNICORN ‘Use of Needleprick Investigation to Collate Objective Rebound Notifications’ Can we adapt Xpert HIV VL and HIV Qual cartridges for PoC needlestick pVL measurement? Recruited participants at St Mary’s Hospital, London N=40 20 WITH UNDETECTABLE pVL – all <20 copies/ml 20 WITH DETECTABLE pVL – wide range of values

Study Protocol: Each Participant x1 x4 4 CARTRIDGES: 100ul WB Finger-prick sample SPIN PVL assay Roche Taqman Certified clinical lab HIV-1 Qual x2 HIV-1 Viral Load x2

The ‘SPIN’ step Microcentrifuge Portable Cheap 3 minute spin

Finger-Prick Sample Prep HIV-1 Qual Cartridge HIV-1 Viral Load Cartridge 100µl blood ADD TO 1000µl buffer ADD TO CARTRIDGE 100µl blood ADD TO 100µl PBS SPIN for 3 mins REMOVE 100µl 1000µl buffer ADD TO CARTRIDGE 100µl blood ADD TO 900 µl PBS ADD TO CARTRIDGE 100µl blood ADD TO 1000 µl PBS in EPPENDORF SPIN for 3 mins REMOVE 1000µl ADD TO CARTRIDGE

WHAT ABOUT FOR DETECTABLE VIRAEMIA?

Range of Detectable Viraemia (n=20) Mean 95,219 copies/ml Range 33-1,514,378 copies/ml

What does this tell us? (Part 1) Can’t do pVL from WB using standard protocols Introducing spin allows accurate indentification of undetectable viraemia Introducing spin impacts sensitivity for quantification of detectable viraemia With HIV Viral load assay a finger-prick PoC approach Can we still use this protocol, accepting a higher LLD?

Analysis according to Roche pVL

Analysis according to Roche pVL SPIN STEP PRESERVES CONCORDANCE WITH ROCHE AT PVL > 1000 COPIES/ML

Excellent concordance for all pVL >1000 copies/ml

What does this tell us? (Part 2) Can’t do pVL from WB using standard protocols Introducing spin allows accurate identification of undetectable viraemia Introducing spin impacts sensitivity for quantification of detectable viraemia For UNDETECTABLE viraemia: PoC approach gives 100% agreement with Roche For DETECTABLE viraemia: PoC approach is accurate for pVL >1000 copies/ml

Acknowledgements Participants of UNICORN Peter Medawar Building, Oxford Jodi Meyerowitz Imperial College, London Heather Lewis Kristen Kuldanek John Thornhill Panagiotis Pantelidis David Muir Sarah Fidler Cepheid Georgina Timson Alice Bonnissent Poster MOPEB0264
 Monday, 24 July 2017, 12:30 – 14:30 www.cherub.uk.net Twitter: @ukcherub